Aviado · Research
Longevity Daily
Tuesday, July 28, 2026
Listen
Today's Brief
Today's standout story reveals how your brain's glymphatic waste-clearance system — the very mechanism that flushes out amyloid-β overnight — deteriorates in lockstep with Alzheimer's progression, and why sleep quality may be your single most powerful tool against it. Separately, a study in Alzheimer's & Dementia delivers a long-view warning: high blood pressure in midlife quietly predicts memory loss well into your 90s. A three-year placebo-controlled trial makes a surprisingly strong case for the humble daily multivitamin, and Life Biosciences has dosed the first human with a cellular reprogramming therapy — a genuine milestone for longevity medicine.
10 stories4 peer-reviewed2 trials1 Aviado original
Cognitive Health & Neuroprotection
Your Brain Has a Waste-Clearance System. When It Fails, Alzheimer's Follows.
The brain's glymphatic network drains cerebrospinal fluid and flushes out protein waste like misfolded amyloid-β — and a new review confirms that its age-related decline maps directly onto every established marker of Alzheimer's disease progression, from amyloid burden to tau pathology to cognitive scores. Researchers using a specialized MRI technique (DTI-ALPS) can now measure glymphatic flow non-invasively, giving clinicians an early-warning window before symptoms appear. The critical takeaway: glymphatic drainage peaks during deep slow-wave sleep and is enhanced by the lateral (side) sleeping position, meaning sleep quality is one of the most powerful and most overlooked levers you have for long-term brain protection.
Read more →High Blood Pressure in Your 40s Quietly Erodes Memory Well Into Your 90s
A study published in Alzheimer's & Dementia finds that midlife hypertension is independently associated with significantly lower semantic memory scores in adults aged 90 and older — even after controlling for other health factors. The effect spans four to five decades, meaning the blood pressure decisions you make today are shaping what you'll remember in your final years. If you're treating borderline hypertension as a 'watch and wait' situation, this study argues for a more aggressive stance.
Read more →Supplements & Compounds
A Daily Multivitamin Beats Placebo for Functional Health in Older Adults — Three-Year Trial
In a three-year, placebo-controlled trial from Augusta University, older adults taking a daily multivitamin showed significantly better functional health outcomes — including cardiovascular-related measures and overall quality of life — compared to those on placebo. Lead cardiologist Dr. Yanbin Dong calls it 'a simple, low-risk strategy to help older adults maintain cardiovascular-related functional health.' At a cost of a few dollars per month, the risk-reward calculation is becoming increasingly difficult to argue with.
Read more →Seaweed Compound Fucoidan Passes Its First Rigorous RCT for BPH Relief
A randomized, double-blind, placebo-controlled trial finds that daily fucoidan — a sulfated polysaccharide extracted from the Japanese seaweed Undaria pinnatifida — significantly improved urinary flow symptoms and quality of life in men with moderate benign prostatic hyperplasia (BPH). This is notable because fucoidan is rarely evaluated in rigorous clinical trials, making this RCT evidence meaningful for the roughly 50% of men over 50 who manage BPH symptoms. Worth a conversation with a physician if BPH is on your radar.
Read more →Low B12 Can Look Exactly Like Aging — and Two Popular Longevity Drugs Make It Worse
Vitamin B12 deficiency produces symptoms so similar to normal aging — fatigue, cognitive fog, balance problems, nerve tingling — that it's routinely overlooked in older adults. The catch for the longevity-minded: both metformin (widely used off-label for longevity) and proton pump inhibitors are known to impair B12 absorption, meaning some health-optimizers may be inadvertently manufacturing a deficiency. Standard bloodwork may miss it; clinicians increasingly recommend testing methylmalonic acid as a more sensitive marker of true B12 status.
Read more →Research & Papers
Metformin's Blood-Sugar Secret Was in the Brain All Along
For six decades, metformin was understood to work primarily on the liver — but new research reveals the brain is a key site of action for how the drug regulates blood glucose. This mechanistic reframe has real implications: it may explain some of the broader metabolic and cognitive effects reported by users, and raises new questions about how metformin's central nervous system activity plays out over long-term, off-label use. For the large and growing number of longevity enthusiasts taking metformin prophylactically, this finding adds important nuance to the risk-benefit picture.
Read more →The Thymus Secretes an Anti-Inflammation Peptide — and It Disappears as We Age
Best known as the site of T cell maturation, the thymus also secretes a peptide called thymulin that regulates inflammatory signaling in myeloid immune cells and helps the immune system identify and destroy cancerous cells. By age 50, the thymus has largely been replaced by fat in most people, and this new research identifies the resulting drop in thymulin as a plausible driver of the chronic inflammation and elevated cancer risk that characterize aging. The finding adds scientific weight to research programs targeting thymic regeneration as a longevity intervention.
Read more →Aviado Research: Longevity Science Analysis
Aviado Research has published a new review synthesizing current evidence across key topics in biological aging and healthspan optimization. As Aviado's editorial team evaluates the latest science, this analysis represents their most current thinking for practitioners and informed health optimizers alike. Visit Aviado Research for the full analysis.
Read the full Aviado analysis →Lifestyle & Nutrition
Singapore Leads the World in Lifespan — But Residents Spend More Years Sick
Singapore tops global life expectancy rankings, but researchers at the National University of Singapore have documented a striking caveat: residents spend a disproportionately large share of their final years in poor health, revealing a significant morbidity gap between how long people live and how well they live. 'Singapore's longevity reflects deliberate long-term policy rather than any single cause,' says study author Dr. Marie Ng. The finding is a sharp reminder that the real goal of longevity medicine is compressing illness into as few final years as possible — not simply adding years to the calendar.
Read more →Industry & Policy
ER-100 Becomes the First Cellular Reprogramming Therapy Ever Tested in a Human
On June 9, 2026, Life Biosciences dosed the first patient with ER-100 — a gene therapy deploying Yamanaka factors to partially reprogram aged cells — marking a genuine historic first in longevity medicine. The Phase 1 trial targets damaged retinal cells as an initial proof-of-concept for the broader cellular rejuvenation approach described in a recent Nature feature. If ER-100 establishes a clean safety profile, it would validate the entire epigenetic reprogramming framework and open the door to a new generation of longevity therapies targeting tissue aging across the body.
Read more →